Evidence map›Paper›PMID 38799695›Full record

ArticleInternational journal of nanomedicine2024

Preparation of Hematoporphyrin-Poly(Lactic Acid) Nanoparticles Encapsulated Perfluoropentane/Salicylic Acid for Enhanced US/CEST MR Bimodal Imaging.

Liqiong Ding, Fengnan Xu, Binhua Luo, Liyuan Cheng, Lingping Huang, Yanlong Jia, Jieqiong Ding

Abstract read
In one paragraph

Article in International journal of nanomedicine, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Article
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Liqiong Ding *Xianning Medical College, Hubei University of Science and Technology, Xianning, Hubei Province, People's Republic of China.ORCID 0000-0003-0508-7531
Fengnan Xu *Xianning Medical College, Hubei University of Science and Technology, Xianning, Hubei Province, People's Republic of China.
Binhua Luo *Xianning Medical College, Hubei University of Science and Technology, Xianning, Hubei Province, People's Republic of China.ORCID 0000-0002-5391-3933
Liyuan ChengXianning Medical College, Hubei University of Science and Technology, Xianning, Hubei Province, People's Republic of China.ORCID 0009-0000-3013-4550
Lingping HuangDepartment of Medical Ultrasound, Xianning Central Hospital, The First Affiliated Hospital of Hubei University of Science and Technology, Xianning, Hubei Province, People's Republic of China.ORCID 0009-0006-6183-2670
Yanlong JiaDepartment of Radiology, Xiangyang Central Hospital, Affiliated Hospital of Hubei University of Arts and Science, Xiangyang, Hubei Province, People's Republic of China.
Jieqiong DingXianning Medical College, Hubei University of Science and Technology, Xianning, Hubei Province, People's Republic of China.ORCID 0009-0007-9500-7633

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Medical imaging modalities, such as magnetic resonance imaging (MRI), ultrasound, and fluorescence imaging, have gained widespread acceptance in clinical practice for tumor diagnosis. Each imaging modality has its own unique principles, advantages, and limitations, thus necessitating a multimodal approach for a comprehensive disease understanding of the disease process. To enhance diagnostic precision, physicians frequently integrate data from multiple imaging modalities, driving research advancements in multimodal imaging technology research. Methods: In this study, hematoporphyrin-poly (lactic acid) (HP-PLLA) polymer was prepared via ring-opening polymerization and thoroughly characterized using FT-IR, Results: We designed and prepared a novel dual-mode nanoimaging probe SA/PFP@HP-PLLA NPs. PFP enhanced US imaging, while salicylic acid bolstered CEST imaging. With an average size of 74.43 ± 1.12 nm, a polydispersity index of 0.175 ± 0.015, and a surface zeta potential of -64.1 ± 2.11 mV. These NPs exhibit excellent biocompatibility and stability. Both in vitro and in vivo experiments confirmed the SA/PFP@HP-PLLA NP's ability to improve tumor characterization and diagnostic precision. Conclusion: The SA/PFP@HP-PLLA NPs demonstrate promising dual-modality imaging capabilities, indicating their potential for preclinical and clinical use as a contrast agent.

Indexed as

FluorocarbonsHematoporphyrinsMagnetic Resonance ImagingNanoparticlesPolyestersSalicylic AcidAnimalsCell Line, TumorContrast MediaHumansMiceMultimodal ImagingPentanesUltrasonographyContrast MediaFluorocarbonsHematoporphyrinsPentanesperfluoropentanePolyesterspoly(lactide)Salicylic Acidchemical exchange saturation transfercontrast agentperfluoropentanesalicylic acidultrasound imaging

Identifiers

PMID38799695
PMCPMC11127694

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.